There are currently four agents that target IL-23 in clinical use for psoriasis: ustekinumab, which blocks the common p40 subunit of IL-12 and IL-23, and guselkumab, risankizumab, and tildrakizumab, which target the p19 subunit of IL-23. This evidence concerns the gene IL23A and psoriasis.